Xenon Pharmaceuticals Inc.
NASDAQ:XENEBiotechnology
-$0.29 today
- Market cap
- $3.69B
- Beta
- 0.63
- P/E (TTM)
- -12.1
- EPS (TTM)
- -$4.39
Volume 1.28M
Average 1.16M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
Intrinsic Alpha fair value
Locked
Current Price
$37.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -7.4% | +166.4% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -7.4% over three years. Forward estimates point to Revenue at +166.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. NASDAQ:NBIX | $16.94B | $167.40 | Undervalued | 23.8 | +12.67% |
Jazz Pharmaceuticals plc NASDAQ:JAZZ | $15.50B | $241.55 | Undervalued | 476.3 | +34.55% |
Praxis Precision Medicines, Inc. NASDAQ:PRAX | $9.17B | $328.13 | Not rated | -25.0 | +89.47% |
Axsome Therapeutics, Inc. NASDAQ:AXSM | $7.45B | $141.69 | Not rated | -68.6 | -5.32% |
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | $3.24B | $18.75 | Undervalued | 9.7 | -23.19% |
Denali Therapeutics Inc. NASDAQ:DNLI | $3.00B | $18.74 | Not rated | -8.7 | +6.06% |
Supernus Pharmaceuticals, Inc. NASDAQ:SUPN | $1.73B | $29.72 | Overvalued | -87.6 | -36.70% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -12.14% |
Anavex Life Sciences Corp. NASDAQ:AVXL | $86.53M | $0.93 | Not rated | -5.9 | -78.94% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -85.30% |
Continue the stock analysis
Jump to another research area for this company.